Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience

Table 1 Univariate analysis for local control, loco-regional control & disease free survival

Prognostic factor	Patients	5-yr LC	p-value	5-yr LRC	p-value	5-yr DFS	p-value
*Age*
> 54 yrs	110	46.8%	0.057	36.2%	0.067	35.0%	0.123
≤ 54 yrs	154	65.1%		53.6%		49.0%
*HP Grade*
NOS	232	55.2%	0.115	44.2%	0.153	41.8%	0.241
WD	04	33.3%		33.0%		33.3%
MD	05	80.0%		40.0%		40.0%
PD	23	73.7%		64.2%		55.2%
*T stage*
T1-T2	53	73%	0.004	43.4%	0.079	36.1%	0.078
T3	153	59%		50.7%		49.3%
T4	58	50%		36%		33.8%
*N stage*
N0	64	66.0%	0.212	66.0%	0.001	66.0%	0.001
N1	61	58.1%		54.1%		54.1%
N2-3	139	51.9%		31.9%		27.0%
*Stage Group*
III	96	68.8%	0.005	66.1%	0.001	66.1%	0.001
IV	168	50.3%		34.0%		29.7%
*Primary site*
Oral cavity	18	13.9%	0.001	13.9%	0.012	13.9%	0.026
Oropharynx	118	58.6%		50.7%		47.7%
Hypopharynx	93	59.3%		45.0%		42.9%
Larynx	35	71.9		50.2%		44.4%
*RT dose*
< 70 Gy	51	51.2%	0.280	37.4%	0.125	35.9%	0.142
≥ 70 Gy	213	60.2%		50.5%		45.6%
*CT cycles*
1–5	96	41.8%	0.022	26.8%	0.009	25.8%	0.011
≥ 6	168	64.5%		54.4%		49.6%
*KPS*
< 80	51	46.4%	0.215	33.0%	0.183	30.3%	0.133
≥ 80	213	60.1%		49.3%		82.2%
*OTT*
≤ 51 days	116	67.7%	0.029	59.9%	0.013	56.5%	0.016
> 51 days	97	51.1%		39.3%		35.5%

LC = local control; LRC = loco-regional control; DFS = disease free survival; NOS = not otherwise specified; WD = well differentiated; MD = moderately differentiated; PD = poorly differentiated; RT = radiotherapy; CT = chemotherapy; KPS = Karnofsky Performance Status; OTT = overall treatment time